When can maximal efficacy occur with repeat botulinum toxin injection in upper limb spastic paresis?
Open Access
- 18 November 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 3 (1) , fcaa201
Abstract
Repeated injection cycles with abobotulinumtoxinA, a botulinum toxin type A, are recommended in current clinical guidelines as a treatment option for adults with upper limb spastic paresis. However, the magnitude of the maximal therapeutic effect of repeated abobotulinumtoxinA treatment across different efficacy parameters and the number of injection cycles required to reach maximal effect remain to be elucidated. Here, we present a post hoc exploratory analysis of a randomized, double-blind, placebo-controlled trial (12–24 weeks; NCT01313299) and open-label extension study (up to 12 months; NCT0131331), in patients aged 18–80 years with hemiparesis for ≥6 months after stroke/traumatic brain injury. Two inferential methods were used to assess the changes in efficacy parameters after repeat abobotulinumtoxinA treatment cycles: Mixed Model Repeated Measures analysis and Non-Linear Random Coefficients analysis. Using the latter model, the expected maximal effect size (not placebo-controlled) and the number of treatment cycles to reach 90% of this maximal effect were estimated. Treatment responses in terms of passive and perceived parameters (i.e. modified Ashworth scale in primary target muscle group, disability assessment scale for principal target for treatment or limb position, and angle of catch at fast speed) were estimated to reach near-maximal effect in two to three cycles. Near-maximal treatment effect for active parameters (i.e. active range of motion against the resistance of extrinsic finger flexors and active function, assessed by the Modified Frenchay Scale) was estimated to be reached one to two cycles later. In contrast to most parameters, active function showed greater improvements at Week 12 (estimated maximal change from baseline-modified Frenchay Scale overall score: +0.8 (95% confidence interval, 0.6; 1.0) than at Week 4 (+0.6 [95% confidence interval, 0.4; 0.8]). Overall, the analyses suggest that repeated treatment cycles with abobotulinumtoxinA in patients chronically affected with upper limb spastic paresis allow them to relearn how to use the affected arm with now looser antagonists. Future studies should assess active parameters as primary outcome measures over repeated treatment cycles, and assess efficacy at the 12-week time-point of each cycle, as the benefits of abobotulinumtoxinA may be underestimated in the studies of insufficient duration. Abbreviated summary In this post hoc analysis of repeated abobotulinumtoxinA injection cycles in upper limb spastic paresis, Gracies et al. used statistical modelling to elucidate the maximal therapeutic effect of abobotulinumtoxinA. Notably, the number of injections required to reach this maximal effect was higher for active (e.g. active function) compared with passive (e.g. tone) parameters.Keywords
This publication has 15 references indexed in Scilit:
- Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache [RETIRED]Neurology, 2016
- Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trialThe Lancet Neurology, 2015
- Systematic Literature Review of AbobotulinumtoxinA in Clinical Trials for Adult Upper Limb SpasticityAmerican Journal of Physical Medicine & Rehabilitation, 2015
- Five-step clinical assessment in spastic paresis.2010
- Article 10: Relationship Between Active Function and Tone in a Placebo-Controlled Study of Botulinum Neurotoxin vs Tizanidine in Upper Limb SpasticityArchives of Physical Medicine and Rehabilitation, 2009
- The impact of analytic method on interpretation of outcomes in longitudinal clinical trialsInternational Journal Of Clinical Practice, 2008
- Repeated dosing of botulinum toxin type A for upper limb spasticity following strokeNeurology, 2004
- Does reducing spasticity translate into functional benefit? An exploratory meta-analysisJournal of Neurology, Neurosurgery & Psychiatry, 2004
- Inter- and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticityArchives of Physical Medicine and Rehabilitation, 2002
- Botulinum treatment of spasticity: why is it so difficult to show a functional benefit?Current Opinion in Neurology, 2001